Market capitalization | $1.22b |
Enterprise Value | $1.29b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 7.24 |
EV/Sales (TTM) EV/Sales | 1.17 |
P/S ratio (TTM) P/S ratio | 1.11 |
P/B ratio (TTM) P/B ratio | 1.03 |
Sales growth (TTM) Sales growth | -13.02% |
Turnover (TTM) Turnover | $1.10b |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
9 Analysts have issued a Omnicell, Inc. forecast:
9 Analysts have issued a Omnicell, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net profit | -20 -20 |
461%
461%
|
|
Depreciation and amortization | 96 96 |
4%
4%
|
|
Share compensation | 55 55 |
19%
19%
|
|
Operating cash flow | 181 181 |
133%
133%
|
|
Investments | 55 55 |
9%
9%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | 140 140 |
362%
362%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Randall Lipps |
Employees | 3,650 |
Founded | 1992 |
Website | www.omnicell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.